PuSH - Publikationsserver des Helmholtz Zentrums München

Kirstein, A. ; Schmid, T.E. ; Combs, S.E.

The role of miRNA for the treatment of MGMT unmethylated glioblastoma multiforme.

Cancers 12:1099 (2020)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Glioblastoma multiforme (GBM) is the most common high-grade intracranial tumor in adults. It is characterized by uncontrolled proliferation, diffuse infiltration due to high invasive and migratory capacities, as well as intense resistance to chemo- and radiotherapy. With a five-year survival of less than 3% and an average survival rate of 12 months after diagnosis, GBM has become a focus of current research to urgently develop new therapeutic approaches in order to prolong survival of GBM patients. The methylation status of the promoter region of the O-6-methylguanine-DNA methyltransferase (MGMT) is nowadays routinely analyzed since a methylated promoter region is beneficial for an effective response to temozolomide-based chemotherapy. Furthermore, several miRNAs were identified regulating MGMT expression, apart from promoter methylation, by degrading MGMT mRNA before protein translation. These miRNAs could be a promising innovative treatment approach to enhance Temozolomide (TMZ) sensitivity in MGMT unmethylated patients and to increase progression-free survival as well as long-term survival. In this review, the relevant miRNAs are systematically reviewed.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Glioblastoma ; Mirna ; Mgmt ; Survival ; Radiotherapy ; Chemotherapy ; Temozolomide ; Translational Medicine; Temozolomide Plus O-6-benzylguanine; Newly-diagnosed Glioblastoma; Dna-repair Protein; Human Glioma-cells; Cancer Stem-cells; Phase-ii; Malignant Progression; Adjuvant Temozolomide; Current Strategies; Genetic Pathways
ISSN (print) / ISBN 2072-6694
Zeitschrift Cancers
Quellenangaben Band: 12, Heft: 5, Seiten: , Artikelnummer: 1099 Supplement: ,
Verlag MDPI
Verlagsort St Alban-anlage 66, Ch-4052 Basel, Switzerland
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Radiation Medicine (IRM)